Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy

被引:2
|
作者
Atik, Alp [1 ,2 ]
Hu, Yijun [3 ]
Yu, Honghua [4 ]
Yang, Chun [5 ]
Cai, Bin [1 ]
Tao, Yijing [1 ]
Li, Dongli [1 ]
Chen, Yan [1 ]
Lu, Li [1 ]
Li, Guodong [6 ]
Yuan, Ling [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 295 Xichang Rd, Kunming 650031, Yunnan, Peoples R China
[2] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia
[3] Shanwei Project Vis Eye Hosp, Shanwei, Peoples R China
[4] Gen Hosp Guangzhou Mil Command PLA, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China
[5] Peoples Hosp Gejiu City, Dept Ophthalmol, Gejiu, Peoples R China
[6] Nanchang Univ, Affiliated Hosp 2, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China
来源
BMC OPHTHALMOLOGY | 2017年 / 17卷
基金
中国国家自然科学基金;
关键词
Central serous chorioretinopathy (CSCR); Photodynamic therapy (PDT); Visual field; Macular sensitivity; Automated static perimetry; VISUAL FUNCTION; RETINAL SENSITIVITY; FUNDUS PERIMETRY; VERTEPORFIN; ACUITY; RANIBIZUMAB; THRESHOLD; FLUENCE; VISION; UPDATE;
D O I
10.1186/s12886-017-0535-y
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: To evaluate the macular sensitivity changes after half-dose photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSCR). Methods: Eighteen patients (26 eyes) with chronic CSCR were recruited in the same hospital between April 2011 and December 2012. All patients were treated with one session of half-dose PDT after complete ophthalmic examination. Macular sensitivity examination was performed at baseline and 1, 3 and 6 months post-treatment. Mean sensitivity (MS) of the central 10 degrees (10 degrees) and 4 degrees (4 degrees), mean deviation (MD) and pattern standard deviation (PSD) on automated static perimetry (Humphrey Field Analyzer II-750) were used for analysis. Results: There was significant improvement of the 10 degrees MS from baseline (29.76 +/- 1.51 dB) to 1 month (31.74 +/- 1.56 dB), 3 months (31.51 +/- 1.38 dB) and 6 months (31.19 +/- 1.61 dB) after treatment (P < 0.001). The 4 degrees MS was also significantly improved with half-dose PDT from baseline (28.96 +/- 1.78 dB) to 1 month (32.41 +/- 1.66 dB), 3 months (32.46 +/- 1.50 dB) and 6 months (31.90 +/- 1.84 dB) post-treatment (P < 0.001). MD was improved from baseline (-3.39 +/- 0.89 dB) to 1 month (-1.96 +/- 0.29 dB), 3 months (-1.94 +/- 0.29 dB) and 6 months (-2.45 +/- 0.13) post-treatment (P = 0.004). PSD also improved from 1.97 +/- 0.24 dB at baseline to 1.47 +/- 0.27 dB, 1.34 +/- 0.24 dB, and 1.53 +/- 0.24 dB (P = 0.001) at 1, 3 and 6 months after treatment, respectively. Conclusion: Macular sensitivity in CSCR can be improved by half-dose PDT, along with improvement of visual acuity and retinal thickness. The treatment outcome at 1 month may be a predictor of the final treatment response.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Half-Dose Verteporfin Combined with Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
    Liu, Chun-Fu
    Chen, Lee-Jen
    Tsai, Shawn H.
    Lai, Chi-Chun
    Chan, Wei-Chun
    Wu, Wei-Chi
    Wang, Nan-Kai
    Chen, Kuan-Jen
    Hwang, Yih-Shiou
    Chen, Yen-Po
    Yeung, Ling
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2014, 30 (05) : 400 - 405
  • [22] Half-fluence Versus Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy REPLY
    Nicolo, Massimo
    Traverso, Carlo Enrico
    Musetti, Donatella
    Piccolino, Felice Cardillo
    Eandi, Chiara M.
    Alovisi, Camilla
    Grignolo, Federico M.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (01) : 205 - 206
  • [23] No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
    Andrea Servillo
    Riccardo Sacconi
    Ilaria Zucchiatti
    Elena Grachova
    Lea Querques
    Francesco Prascina
    Beatrice Tombolini
    Giorgio Dorin
    Martin Mainster
    Francesco Bandello
    Giuseppe Querques
    Ophthalmology and Therapy, 2023, 12 : 2199 - 2208
  • [24] No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
    Servillo, Andrea
    Sacconi, Riccardo
    Zucchiatti, Ilaria
    Grachova, Elena
    Querques, Lea
    Prascina, Francesco
    Tombolini, Beatrice
    Dorin, Giorgio
    Mainster, Martin
    Bandello, Francesco
    Querques, Giuseppe
    OPHTHALMOLOGY AND THERAPY, 2023, 12 (04) : 2199 - 2208
  • [25] Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
    Cheng, Zhihang
    Babiker, Salma
    Lenfestey, Pauline
    Beare, Nick
    Pearce, Ian A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [26] Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy
    R Uetani
    Y Ito
    K Oiwa
    K Ishikawa
    H Terasaki
    Eye, 2012, 26 : 640 - 649
  • [27] Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy
    Tseng, Chien-Chi
    Chen, San-Ni
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2015, 99 (08) : 1070 - 1077
  • [28] Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy
    Uetani, R.
    Ito, Y.
    Oiwa, K.
    Ishikawa, K.
    Terasaki, H.
    EYE, 2012, 26 (05) : 641 - 648
  • [29] Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy
    Liu, Hsin-Yu
    Yang, Chang-Hao
    Yang, Chung-May
    Ho, Tzyy-Chang
    Lin, Chang-Ping
    Hsieh, Yi-Ting
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 167 : 57 - 64
  • [30] The safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy
    Feenstra, H. M. A.
    Diederen, R. M. H.
    Lamme, M. J. C. M.
    Fauser, S.
    Downes, S. M.
    Schlingemann, R. O.
    Hoyng, C. B.
    van Dijk, E. H. C.
    Boon, C. J. F.
    ACTA OPHTHALMOLOGICA, 2022, 100 : 19 - 19